AAVantgarde Bio Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 27

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $141M

  • Investors
  • 14

AAVantgarde Bio General Information

Description

Developer of a gene therapy technology designed for inherited retinal disorders. The company builds on proprietary Adeno-Associated Viral (AAV) vector platforms to address the gene therapy cargo capacity limitations of AAV vectors and deliver large genes to ocular and non-ocular tissues, enabling patients to deliver large genes to tissues and cells in vivo.

Contact Information

Website
www.aavantgarde.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Via Varese 16/B
  • 00185 Rome
  • Italy
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • Via Varese 16/B
  • 00185 Rome
  • Italy

AAVantgarde Bio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AAVantgarde Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series B) 03-Nov-2025 $141M Completed Clinical Trials - Phase 2
3. Early Stage VC (Series A) 06-Jun-2023 Completed Clinical Trials - Phase 2
2. Seed Round 30-Jun-2021 $4.46M $4.46M Completed Clinical Trials - Phase 2
1. Accelerator/Incubator Completed Clinical Trials - Phase 2
To view AAVantgarde Bio’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

AAVantgarde Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a gene therapy technology designed for inherited retinal disorders. The company builds on proprietary Adeno
Drug Discovery
Rome, Italy
27 As of 2024

Barcelona, Spain
 

Durham, NC
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AAVantgarde Bio Competitors (2)

One of AAVantgarde Bio’s 2 competitors is SpliceBio, a Venture Capital-Backed company based in Barcelona, Spain.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
SpliceBio Venture Capital-Backed Barcelona, Spain
Atsena Therapeutics Venture Capital-Backed Durham, NC
You’re viewing 2 of 2 competitors. Get the full list »

AAVantgarde Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AAVantgarde Bio Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Amgen Ventures Corporate Venture Capital Minority
Athos (Private Equity) Venture Capital Minority
British Columbia Investment Management Asset Manager Minority
CDP Venture Capital (Rome) Venture Capital Minority
NEVA SGR Venture Capital Minority
You’re viewing 5 of 14 investors. Get the full list »

Ready to get started?

Request a free trial

AAVantgarde Bio Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Aavantgarde Bio Uk London, United Kingdom 2023

AAVantgarde Bio FAQs

  • When was AAVantgarde Bio founded?

    AAVantgarde Bio was founded in 2021.

  • Where is AAVantgarde Bio headquartered?

    AAVantgarde Bio is headquartered in Rome, Italy.

  • What is the size of AAVantgarde Bio?

    AAVantgarde Bio has 27 total employees.

  • What industry is AAVantgarde Bio in?

    AAVantgarde Bio’s primary industry is Drug Discovery.

  • Is AAVantgarde Bio a private or public company?

    AAVantgarde Bio is a Private company.

  • What is AAVantgarde Bio’s current revenue?

    The current revenue for AAVantgarde Bio is .

  • How much funding has AAVantgarde Bio raised over time?

    AAVantgarde Bio has raised $211M.

  • Who are AAVantgarde Bio’s investors?

    Amgen Ventures, Athos (Private Equity), British Columbia Investment Management, CDP Venture Capital (Rome), and NEVA SGR are 5 of 14 investors who have invested in AAVantgarde Bio.

  • Who are AAVantgarde Bio’s competitors?

    SpliceBio and Atsena Therapeutics are competitors of AAVantgarde Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process